Pfizer
Long

PFE - our Long Call materializes

106
Our recent recommended top pick from Healthcare sector: PFE: released better than expected financial results; raised full year guidance;
The company’s earnings per share (EPS) in the second quarter stood at $0.60, surpassing the consensus estimate of $0.46. Revenue came in at $13.3 billion, also above the projected $13.03 billion.

Pfizer reported adjusted research and development expenses of $2.67 billion for the period, compared to the estimated $2.83 billion.

Looking forward, the pharmaceutical giant now projects FY2024 EPS of $2.45 to $2.65, up from the previous guidance of $2.15 to $2.35, and above the consensus estimate of $2.38.

Declinazione di responsabilità

Le informazioni ed i contenuti pubblicati non costituiscono in alcun modo una sollecitazione ad investire o ad operare nei mercati finanziari. Non sono inoltre fornite o supportate da TradingView. Maggiori dettagli nelle Condizioni d'uso.